Rigel Pharmaceuticals published final long-term results from the Phase 1/2 ARROW study of pralsetinib (Gavreto) in RET fusion-positive metastatic NSCLC in the Journal of Clinical Oncology. The updated analysis adds 42 months of follow-up to previously reported data, maintaining a focus on response durability and safety in a biomarker-defined population. Among patients with measurable disease (n=259), the overall response rate was reported as 70% (7% complete responses, 63% partial responses). Rigel said the efficacy remained robust while safety findings were consistent with earlier reports. Rigel also highlighted three treatment-related deaths in treatment-naive patients in Asia, attributed to events including pneumonia and interstitial lung disease; the company reported no new safety signals and no hypersensitivity reactions in patients previously treated with immunotherapies. The update reinforces the clinical value of selective RET inhibition and the importance of early biomarker testing for treatment sequencing.